Venetoclax for Treating Chronic Lymphocytic Leukaemia: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

Venetoclax is licensed to treat relapsed or refractory (R/R) chronic lymphocytic leukaemia (CLL). As part of the Single Technology Appraisal (STA) ID944, the National Institute for Health and Care Excellence (NICE) invited AbbVie, the manufacturer, to submit evidence on the use of venetoclax, within...

Full description

Saved in:
Bibliographic Details
Published in:Pharmacoeconomics
Main Authors: Mistry, Hema, Nduka, Chidozie, Connock, Martin, Colquitt, Jill, Mantopoulos, Theodoros, Loveman, Emma, Walewska, Renata, Mason, James
Format: Artigo
Language:Inglês
Published: Springer International Publishing 2017
Subjects:
Review Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC5840199/
https://ncbi.nlm.nih.gov/pubmed/29222670
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s40273-017-0599-9
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items